Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery

European Journal of Pharmacology

Volumn 448, Issue 2-3, 2002, Pages 193-200

  Broglio, Fabio ^a   Guarracino, Fabio ^b   Benso, Andrea ^a   Gottero, Cristina ^a   Prodam, Flavia ^a   Granata, Riccarda ^a   Avogadri, Enrico ^a   Muccioli, Giampiero ^c   Deghenghi, Romano ^d   Ghigo, Ezio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Umberto i Hospital   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d Ardana   (France)

Author keywords

Cardiac performance; Coronary artery disease; GH Secretagogue; Ghrelin; GHRH (growth hormone releasing hormone); Hexarelin

Indexed keywords

GROWTH HORMONE RELEASING FACTOR; HEXARELIN; HUMAN GROWTH HORMONE; INOTROPIC AGENT; RECOMBINANT HORMONE; GROWTH HORMONE; OLIGOPEPTIDE;

ADULT; ARTERY CATHETERIZATION; ARTICLE; BODY MASS; CENTRAL VENOUS PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG ACTIVITY; DRUG MECHANISM; EXTRACORPOREAL CIRCULATION; GENERAL ANESTHESIA; HEART FUNCTION; HEART INDEX; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART OUTPUT; HEART VENTRICLE PRESSURE; HEMODYNAMICS; HORMONE DEFICIENCY; HUMAN; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PULMONARY ARTERY; SYSTEMIC VASCULAR RESISTANCE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; ANALYSIS OF VARIANCE; BLOOD; COMPARATIVE STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; METHODOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; PATHOPHYSIOLOGY;

ANALYSIS OF VARIANCE; COMPARATIVE STUDY; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; GROWTH HORMONE; HUMAN; MALE; MIDDLE AGE; OLIGOPEPTIDES; SOMATOTROPIN-RELEASING HORMONE; STATISTICS, NONPARAMETRIC; STROKE VOLUME; SUPPORT, NON-U.S. GOV'T; VENTRICULAR DYSFUNCTION, LEFT; GROWTH HORMONE-RELEASING HORMONE; HUMANS; MIDDLE AGED;

EID: 0037135031     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)01934-9     Document Type: Article

References (51)

1. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia
2. Acquired growth hormone resistance in patients with chronic heart failure: Implications for therapy with growth hormone
3. Role of endothelial cells in modulation of contractility induced by hexarelin in rat ventricle
4. Cardiac effects of hexarelin in hypopituitary adults
5. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans
6. Radionuclide angiocardiographic evaluation of the cardiovascular effects of recombinant human IGF-I in normal adults
7. Identification and characterization of a new growth hormone-releasing peptide receptor in the heart
8. Endocrine stress parameters during TIVA with remifentenal or sufentanil
9. Activity of GH/IGF-I axis in patients with dilated cardiomyopathy
10. Normal IGF-I and enhanced IGFBP-3 response to very low rhGH dose in patients with dilated cardiomyopathy
11. Patients with dilated cardiomyopathy show reduction of the somatotroph responsiveness to GHRH both alone and combined with arginine
12. GH-independent cardiotrophic activities of GHRPs in normal subjects, in patients with growth hormone-deficiency or idiopathic or ischemic cardiomyopathy
13. Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy
14. Identification, characterization, and biological activity of specific receptors for natural (ghrelin) and synthetic growth hormone secretagogues and analogs in human breast carcinomas and cell lines
15. Growth hormone and the heart
16. Hexarelin, a growth hormone-releasing peptide, discloses protectant activity against cardiovascular damage in rats with isolated growth hormone deficiency
17. Tissue concentration of somatomedin C: Further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action
18. Cardiovascular and metabolic effects of IGF-I at rest and during exercise in humans
19. Acute cardiovascular effects of IGF-I in patients with chronic heart failure
20. Growth hormone and insulin-like growth factor-1 in acute myocardial infarction
21. Dose-response relationships for the effects of growth hormone-releasing factor-(1-44)-NH2 in young adult men and women
22. Biologic activities of growth hormone secretagogues in humans
23. Impaired spontaneous growth hormone secretion in severe dilated cardiomyopathy
24. Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure
25. Positive inotropic effect of growth hormone releasing factor in the guinea-pig cardiac muscles in vitro
26. Growth hormone for the failing heart
27. Growth hormone-releasing activity of hexarelin in humans. A dose-response study
28. GH and the heart: Potential therapeutic use
29. The role of the GH/IGF-I axis for cardiac function and structure
30. Ghrelin is a growth-hormone-releasing acylated peptide from stomach
31. Changes of the Insulin-Like Growth Factor I System during acute myocardial infarction: Implications on left ventricular remodeling
32. Growth hormone-independent cardioprotective effects of hexarelin in the rat
33. The behaviour of hGH and somatomedin C following anaesthesia induction with propofol in comparison with diazepam and thiopental
34. Changes in growth hormone/insulin-like growth factor-1 axis in patients with normal pituitary function and biventricular cardiac failure and hepatic stasis
35. Specific receptors for synthetic GH Secretagogues in the human brain and pituitary gland
36. Growth hormone-releasing peptides and the cardiovascular system
37. Effect of propofol as an agent for anesthetic induction on pituitary-adrenocortical function during anesthesia and surgery
38. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers
39. Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure
40. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation
41. Binding sites for growth hormone-releasing peptide
42. The severity of chronic heart failure due to coronary artery disease predicts the endocrine effects of short-term growth hormone administration
43. The somatotropic system in patients with dilated cardiomyopathy: Relation of IGF-I and its alterations during growth hormone therapy to cardiac function
44. Growth hormone secretagogue binding sites in peripheral human tissues
45. Protectant activity of hexarelin or growth hormone against post-ischemic ventricular dysfunction in hearts from aged rats
46. Peptidomimetic regulation of growth hormone secretion
47. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction
48. Haemodynamic effects of intravenous growth hormone in congestive heart failure
49. Role of growth hormone in chronic heart failure: Therapeutic implications
50. Cardiovascular effects of intracerebroventricularly administered growth hormone-releasing factor in spontaneously hypertensive rat
51. Pretreatment with growth hormone-releasing peptide-2 directly protects against the diastolic dysfunction of myocardial stunning in an isolated, blood-perfused rabbit heart model